Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Surgery. 2020 Jul 24;169(1):34–42. doi: 10.1016/j.surg.2020.06.009

Figure 3A,B and C.

Figure 3A,B and C.

KU757 treatment is effective in treating lenvatinib-resistant cells. WRO-LvR cells were treated with varying concentrations of (A) Lenvatinib and (B) KU757. Cell viability was determined by cellTiter Glo assay. IC50 values indicated the development of lenvatinib resistance (>50 μM for WRO-LvR cells compared to 4.03μM for the parent WRO cells) and the sensitivity of KU757 (1.396 μM for WRO-LvR and 1.589 μM for WRO) in targeting the resistant cells. (C) Immunoblot analysis of PARP cleavage after treatment of WRO (Control) and WRO-LvR cells (middle column) with solvent DMSO, and WRO-LvR cells with 2μM KU757 to evaluate cell death by measuring for PARP-cleavage. KU757 demonstrated increased cell death with PARP-cleavage in the WRO-LvR cells.